

Conflict of Interest Disclosure and Resolution & Core Competencies

2nd Annual Southern California Genitourinary Cancer Research Forum

February 28, 2025

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Aditya Bagrodia, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Leslie Ballas, MD	Consultant for MDxHealth.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
David J. Benjamin, MD	Consultant for AIMEDBIO, Astellas, AVEO Oncology, Bayer, Eisai, EMD Serono (Merck), Exelixis, Janssen (Johnson & Johnson), and Seagen (Pfizer). On the Speakers Bureau for Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2 & 4
Alex Chehrazhi-Raffle, MD	Consultant for Eisai, Exelixis, and Pfizer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 4
Yu-Wei Chen, MD, MS	Consultant for Eisai. Grant/Research Support from Gilead Sciences.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2 & 4
Sia Daneshmand, MD	Consultant for AstraZeneca, Bristol-Myers Squibb, CG Oncology, enGene, Ferring Pharmaceuticals, ImmunityBio, Johnson & Johnson, Pacific Edge, Pfizer, Photocure, Protara Therapeutics, Inc., and UroGen Pharma. Stock/Shareholder for TARIS Biomedical (Johnson & Johnson).	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Tanya Barauskas Dorff, MD	Consultant for Astellas, AstraZeneca, and Janssen (Johnson & Johnson). Grant/Research Support from Abbvie, Amgen, and AstraZeneca.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: AMG509, PSCA CAR T cells, carotuximab, Ac225-CEA, and talazoparib</i>	Moderator
Alexandra Drakaki, MD, PhD	Consultant for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, EMD Serono (Merck), Exelixis, Merck, and Seagen (Pfizer).	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6 Moderator
Jun Gong, MD	Consultant for Agenus, Bayer, BeiGene, Caper Labs, Eisai, Genentech, Incyte, Pfizer, Seagen (Pfizer), and Taiho.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Hyung Kim, MD	Other Financial Relationship - License with Crown Bioscience.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Amar U. Kishan, MD	Consultant for Boston Scientific. Grant/Research Support from ArteraAI, Lantheus, Novartis, POINT Biopharma (Eli Lilly), and Varian Medical Systems.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Nataliya Mar, MD	Consultant for AVEO Oncology, EMD Serono, and Pfizer. Grant/Research Support from Gilead Sciences. On the Speakers Bureau for Eisai, and Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Andrea Necchi, MD	Consultant for Astellas, Bristol-Myers Squibb, Catalym, Daiichi Sankyo, Genenta Science, Gilead Sciences, Johnson & Johnson, Merck, and Pfizer. Grant/Research Support from AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, and Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Sumanta K. Pal, MD	Grant/Research Support from Allogene Therapeutics, CRISPR Therapeutics, Eisai, Genentech, Roche, and Pfizer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner Moderator
Arash Rezazadeh Kalebasty, MD	Consultant for AIMEDBIO, AstraZeneca, AVEO Oncology, Bayer, Bicycle Therapeutics, Eisai, Exelixis, and Sumitomo Dainippon Pharma. Grant/Research Support from Amgen, Arvinas, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Eikon Therapeutics, Eisai, Exelixis, Genentech, Immunomedics, Janssen (Johnson & Johnson), Merck, Mirati Therapeutics (Bristol-Myers Squibb), Navire Pharma, Novartis, POINT Biopharma (Eli Lilly), and Seagen (Pfizer). On the Speakers Bureau for Amgen, AVEO Oncology, Bayer, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, Gilead Sciences, Janssen (Johnson & Johnson), Myovant Sciences, Pfizer, and Sanofi.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
John Shin, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4
Brian Shuch, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4
Tyler Stewart, MD	Consultant for Astellas, AstraZeneca, EMD Serono, Pfizer, and Seagen (Pfizer). Grant/Research Support from Grail, Inc.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 4
Abhishek Tripathi, MD	Consultant for Deka Biosciences, Gilead Sciences, and Pfizer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1
Przemyslaw Twardowski, MD	Consultant for Bayer, and EMD Serono On the Speakers Bureau for Astellas, AstraZeneca, AVEO Oncology, Bayer, Janssen (Johnson & Johnson), and Pfizer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Saruparib, TLX-591, and 225 Ac-PSMA-617</i>	1, 3 & 4
Wesley Yip, MD	I do not have any relevant financial relationships with any ineligible companies.	None	4

1. The ACCME defines "relevant" financial relationships" as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an "Ineligible company" as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.